Work

P‐TS‐41 | Implementation of Pathogen Reduced Cryoprecipitated Fibrinogen Complex in a Pediatric Level II Trauma Center

Year: 2023
Type: article
Abstract: Due to the 4–6 h shelf life to evade potential infectious transmission, the wastage rates for Cryo AHF were consistently exceeding our targets of less than 10% waste per quarter and contributing to increased costs. The FDA has approved Pathogen Reduced Cryoprecipitated Fibrinogen Complex (PRCFC) for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. The local blood center initiated the manufacture of PRCFC from amotosalen/UVA-treated plasma to mitigate transfusion transmission risk with a post-thaw shelf life of 5-days. Opportunities for increasing patient safety and decreasing CryoAHF waste were identified. Implementation of PRCFC began in November 2021 of the first fiscal quarter of FY2022 (October to December 2021). Increasing patient safety while decreasing CryoAHF waste was managed as a process improvement project. A retrospective analysis of wastage for CryoAHF vs. PRCFC transfusion was performed for orders placed between 1QFY2021 (October 2020) and 2QFY2023 (March 2023). Steps identified in the project plan included product review, acceptance from physician stakeholders, blood utilization committee approval, IT, and procedure updates. The Transfusion Service determines if CryoAHF or PRCFC is used to fill an order based on clinical diagnosis, age, weight, ABO capability, and inventory. The quarterly wastage rate for CryoAHF ranged from 11.3% to 25.8% with an annual average wastage rate of 16.3%. Following the implementation of PRCFC, the annual average wastage rate has decreased to 5.64%. (Table 1) TABLE 1: Quarterly wastage rate for cryoAHF and PRCFC
Source: Transfusion
Language: English
Subfield: Hematology
Field: Medicine
Open Access status: bronze
OpenAlex ID: W4387572467
FWCI: 0.171
Cites:
Cited by: 1
Related to: 10